A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Phase 3 Active not recruiting 151 enrolled Ionis Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with hereditary transthyretin-mediated amyloid polyneuropathy (hATTR-PN).

Timeline

Start: 2022-01-04
Primary completion: 2029-08
Completion: 2029-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Eplontersen	Antisense oligonucleotide	—	Subcutaneous

A Study to Assess the Long-Term Safety and Efficacy of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Summary

Timeline

Drugs

Indications